Articles from Kanvas Biosciences

Kanvas Biosciences, a full-stack spatial biology and microbial therapeutics company, today announced a new investment from Gates Foundation. Through this investment, Kanvas will develop the world’s first fully synthetic microbiome replacement product designed to treat and prevent maternal environmental enteric dysfunction (EED), a major contributor to maternal undernutrition, low infant birthweight and heightened neonatal health risk. Using global metagenomic datasets and samples for microbial strain identification and isolation, Kanvas will leverage its proprietary spatial microbiome imaging platform to inform the design of defined, complex multi-strain consortia, which will be translated into scalable, reproducible products via the company’s vertically integrated, anaerobic manufacturing platform. These manufacturing capabilities, coupled with Kanvas’ proprietary AI drug discovery models that can be used to accelerate the development of live biotherapeutic products, will support the development of a safe, effective and affordable microbiome therapeutic for clinical evaluation in relevant geographical contexts.

Kanvas Biosciences, a full-stack spatial biology company, today announced results from a clinical trial of fecal microbiota transplantation (FMT) and anti-PD-1 re-induction in microsatellite instability-high (MSI-H) refractory cancers. Presented at the third annual Society for Immunotherapy of Cancer (SITC) meeting, the trial data show that FMT enabled a response to reintroduced anti-PD-1 in patients with anti-PD-1 refractory, MSI-H cancers, and suggest that the gut microbiome affects anti-tumoral immunity in a tumor-agnostic manner.

Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, Pangaea Ventures and more. The fresh capital follows a July 2024 round and brings Kanvas’ total funding to $78 million. The funding will be used to conduct clinical trials for the lead drug candidate in the company’s immuno-oncology program, KAN-001, and advance commercial partnerships that leverage Kanvas’ spatial imaging and manufacturing platform for next generation live biotherapeutic product (LBP) development.

Kanvas Biosciences, the leader in microbiome mapping technology, today announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition transitions Kanvas Biosciences from a technology company with a transformative spatial biology platform to a full-stack therapeutics company with active clinical programs and a new cell banking facility in South San Francisco. The deal also expands the company’s leadership and West Coast presence with the addition of Lee Swem, formerly Federation Bio’s Chief Science Officer, who joined Kanvas Biosciences as Chief Development Officer.